f62519fa-7479-4e20-9ae4-d57f8a1e0e64
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 79
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.720
- INTERFERON_GAMMA_RESPONSE+0.590
- IL6_JAK_STAT3_SIGNALING+0.530
- ALLOGRAFT_REJECTION+0.470
- INFLAMMATORY_RESPONSE+0.470
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.420
- COMPLEMENT+0.410
- TNFA_SIGNALING_VIA_NFKB+0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.340
- APOPTOSIS+0.330
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.350
- WNT_BETA_CATENIN_SIGNALING-0.300
- KRAS_SIGNALING_DN-0.190
- MYC_TARGETS_V2-0.170
- MITOTIC_SPINDLE-0.140
- UNFOLDED_PROTEIN_RESPONSE-0.110
- BILE_ACID_METABOLISM-0.040
- HEME_METABOLISM+0.000
- ESTROGEN_RESPONSE_EARLY+0.010
- PEROXISOME+0.010
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR6013563 | — | cohortMD2 | 0.891 |
| 2 | MDT-AP-2887 | Med | Medulloblastoma | 0.883 |
| 3 | TCGA-75-5126-01A-01R-1755-07 | — | cohortA1 | 0.883 |
| 4 | C3L-00093 | — | cohortA1 | 0.882 |
| 5 | MBCProject_0734_T1K_RNA | — | C | 0.877 |
| 6 | SRR12696731 | — | — | 0.874 |
| 7 | C3N-02087 | — | cohortA1 | 0.873 |
| 8 | SRR934884 | — | — | 0.870 |
| 9 | 70203945-80F8-4FA7-8C99-FEBAD3374103 | — | — | 0.869 |
| 10 | SRR934924 | — | — | 0.869 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.720 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.590 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.530 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.470 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.470 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.420 | Inavolisib | — uncovered |
| COMPLEMENT | 0.410 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.400 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.340 | Inavolisib | — uncovered |
| APOPTOSIS | 0.330 | Idelalisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.270 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.240 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.240 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.240 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.230 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.210 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.190 | Inavolisib | — uncovered |